Table 1. Baseline characteristic of patients at the time of liver biopsy.
| Characteristic |
F3 Fibrosis (n = 171) |
F4 Fibrosis (n = 123) |
P value |
|---|---|---|---|
| Age in yrs., mean ± SE | 49 ± 0.9 | 53 ± 1.1 | 0.007 |
| Male, n (%) | 74 (43) | 77 (63) | 0.001 |
| Race, n (%) | |||
| White | 130 (76) | 100 (81) | 0.31 |
| African-American | 35 (20) | 16 (13) | |
| Other* | 6 (4) | 7 (6) | |
| Liver disease etiology, n (%) | |||
| HCV | 51 (30) | 46 (37) | 0.23 |
| NAFLD | 41 (24) | 23 (19) | |
| ALD | 20 (12) | 20 (16) | |
| Other** | 59 (34) | 34 (28) | |
| Serum albumin (g/dl), mean ± SE | 3.4 ± 0.1 | 3.0 ± 0.1 | <0.0001 |
| ALT (IU/l), mean ± SE | 79 ± 8.3 | 67 ± 9.1 | 0.34 |
| AST (IU/l), mean ± SE | 80 ± 7.2 | 85 ± 7.6 | 0.69 |
| Platelet count, mean ± SE | 193 ± 7.8 | 137 ± 6.7 | <0.0001 |
| FIB-4 score, mean ± SE | 3.1 ± 0.2 | 6.3 ± 0.9 | 0.0003 |
| APRI, mean ± SE | 1.4 ± 0.1 | 1.8 ± 0.3 | 0.13 |
| Decompensated at biopsy, n (%) | 28 (16) | 53 (43) | <0.0001 |
Abbreviations: HCV: Hepatitis C virus; ALD: Alcohol-related liver disease; ALT: Alanine aminotransferase; APRI: AST to Platelet Ratio Index; AST: Aspartate aminotransferase; FIB-4: Fibrosis-4; NAFLD: Nonalcoholic liver disease; SVR: Sustained Viral Response
*Other races include Hispanic (3), Asian (n = 1), Indian (n = 2) and unknown (n = 7).
**Other etiologies include Cryptogenic (n = 27), Autoimmune Hepatitis (n = 17), Multiple etiologies (n = 16), PBC/PSC (n = 11), cardiac (n = 12), HBV (n = 4), Budd-Chiari (n = 2), Caroli Disease (n = 2), Drug-Induced (n = 1), and Sarcoidosis (n = 1)